New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
07:06 EDTNVLS, DYAXDyax and Novellus partner to commercialize Kalbitor in Latin America
Dyax (DYAX) and Novellus (NVLS) announced a strategic partnership for the development and commercialization of Kalbitor (ecallantide) for the treatment of hereditary angioedema and other angioedema indications in select regions in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela. Kalbitor is marketed in the U.S. for the treatment of acute attacks of HAE in patients 16 years of age and older. Dyax will receive an upfront payment and is eligible to receive future sales milestones. Dyax is also eligible to receive royalties on net product sales. Novellus is solely responsible for all costs associated with necessary development, regulatory activities, and the commercialization of Kalbitor in the covered territories.
News For DYAX;NVLS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2016
09:39 EDTDYAXThe Medicines Co. takeout price could be $69/share, says Jefferies
Jefferies analyst Biren Amin believes The Medicines Co.'s (MDCO) acquisition price could be around $69 per share prior to the Phase 2 ORION-1 data results. The analyst says he's received inquiries from investors regarding a potential takeout price following Bloomberg's report that the company has hired advisers to explore a sale. Amin used the recent Dyax (DYAX) acquisition as a comparable proxy. If Medicines were to wait until after the Phase 2 data, it could be acquired for $99 per share should the study results be positive, Amin tells investors in a research note. He keeps a Buy rating on The Medicines Co. with a $50 price target.
09:20 EDTDYAXShire completes acquisition of Dyax for $5.9B
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use